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EDITORIAL REVIEW
Schistosomal glomerulopathies
Schistosomes are blood flukes that parasitize the venous
system of a wide range of animals including birds, cattle and
primates. There are seven human pathogenic species of which
the, most prevalent are S. hematobium, found mainly in Africa,
S. mansoni found in Latin America as well as Africa, and S.
japonicum, endemic in China and the Far East. According to
WHO estimates, some 700 million inhabitants of five continents
are at risk, infection being documented in 300 millions [1].
Pat hogenicity
The pathogenicity of Schistosoma hematobium has been
recognized many centuries before discovery of the parasite
itself by Theodore Bilharz in 1852 [2]. Thus, several ancient
Egyptian papyri referred to a syndrome of hematuria ascribed
to a worm acquired through contact with Nile water, and
described as being resistant to a variety of herbal treatments [3].
That this was indeed S. hematobium is suggested by the
discovery of its characteristic ova in the bladders of well-
preserved Egyptian mummies by appropriate rehydration tech-
niques [4]. Today, oviposition in the lower urinary tract remains
as the main pathogenic feature of S. hematobium.
When S. mansoni and S. japonicum were discovered, their
pathogenicity was still ascribed to oviposition, mainly in the
intestine, mesentery and hepatic portal tracts. All schistosomal
lesions in the lungs, brain, spinal cord, eye and skin are also
caused by metastatic oviposition in these sites.
The classical tissue response to deposited ova is granuloma-
tous [5]. As a consequence of the release of "soluble egg
antigens" (SEA) [6, 7] through micropores in the egg shell, a
cascade of cellular recruitment, activation and release of medi-
ators ends up with the formation of granulomata [8]. These
eventually heal by fibrosis, often associated with calcification,
which are the major hallmarks of chronic morbidity from
schistosomiasis [9].
The kidney and urinary tract in schistosomiasis
The urogenital system is the primary target of S. hematobium
and occasionally S. mansoni infestation. The main initial le-
sions are found in the urinary bladder, in the form of "pseudo-
tubercles," polyps and ulcers. As these lesions heal, they lead
to a wide spectrum of diffuse bladder pathology including
"sandy patches," chronic cystitis, bladder calcification, "cys-
titis cystica" and others [10]. There is evidence that some of
these lesions may predispose to malignancy, villous squamous
cell carcinoma of the bladder being classically linked with
schistosomiasis [111.
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Concomitant lower ureteric involvement with similar chronic
inflammatory lesions often leads to obstruction, and less fre-
quently to vesico-ureteric reflux. Although the ureter usually
succeeds in overcoming the obstruction by adequate dilatation
and hypertrophy of its muscle wall, the kidneys are eventually
prone to suffer the effects of back pressure and ascending
infection. Secondary stone formation further complicates the
picture, which often ends up with chronic renal failure [12].
Morbidity from urinary schistosomiasis is widely variable.
While a British Medical Journal editorial described it as being a
"crippling disease with a tremendous economic loss" [13], a
contemporary leading authority in epidemiological research
emphasized "the lack of significant interference of the parasi-
tosis with general health" [14]! It is now realized that geograph-
ical differences are the reason for this discrepancy. Thus, while
clinically overt lower urinary tract lesions are reported to be as
few as 2% in Nigeria [15], 10% in Liberia [16] and 14% in
Zanzibar [17], they are much more common in Egypt (50%) [18]
and Tanzania (52%) [19].
Upper urinary tract pathology, assessed in different popula-
tions by ultrasonography [20], intravenous urography or
changes in renal function [21] have also shown a wide variation
from 9.7% in adult infested subjects in the Niger [22] to 48% in
infested school children in the Cameroon [23]. Ecological
factors responsible for these variations may include differences
in parasitic strains [24], intensity of infestation [25—27], and host
susceptibility [28].
Schistosomal glomerulopathy
It was only over the past three decades that attention was
drawn to the glomerular lesions associated with schistosomia-
sis, being unrelated to lower urinary tract involvement. Indeed,
the earlier reports came out from Brazil, where only S. mansoni
exists, in patients with hepatosplenic schistosomiasis [29—31].
The initial clinical observations were adequately supported
by a large volume of experimental work, showing glomerular
lesions and/or mesangial immune complex deposits in mice [32,
33], hamsters [34—36], rabbits [37], baboons [38], monkeys [39,
40] and chimpanzees [41] exposed to experimental infection.
Further clinical reports from Brazil [42—44], Puerto Rico [45],
Egypt [46—49], the Sudan [50], Somalia [51], Nigeria [52],
Madagascar [53, 54], Arabia [55], Malaysia [56] and others [57],
confirmed the identity of schistosomal glomerulopathy as a
distinct disease entity. The hallmark of the syndrome is its
independence from any oviposition, being mediated by the
immune response to circulating schistosomal adult worm anti-
gens. For the first time after many centuries dealing with this
parasite, the medical profession then became aware that mor-
bidity from schistosomiasis could be pathogenetically dissoci-
ated from granuloma formation.
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Epidemiologic impact
Like with other chronic complications of schistosomiasis, the
incidence of glomerulopathy seems to be geographically van-
able. Unfortunately, there are no reliable statistical data, most
series being reported from reference centers rather than field
surveys, with only a few exceptions [47, 58]. Furthermore, it is
becoming increasingly clear that overt renal disease in schisto-
somiasis is indeed the tip of an iceberg of much more widely
prevalent subclinical glomerular involvement, which makes it
even more difficult to estimate the true incidence of glomerular
pathology.
In a series of 162 subjects reported by Lehmen et a! [58] from
Brazil, those with intestinal schistosomiasis had higher quanti-
ties of protein in their urines compared with non-infested
subjects. However, only two had overt proteinuria and an
abnormal urinary sediment. In a similar group of 240 Egyptian
patients, Sobh et al [59] reported a 20% incidence of asymp-
tomatic proteinuria among S. mansoni-infected subjects. Renal
biopsies obtained from 15 subjects showed light microscopic
and immunofluorescence appearances compatible with classical
schistosomal glomerulopathy.
The same issue was addressed in a large field study on S.
hematobium-infested subjects by Ezzat et al [47], who reported
Albustix-moderate proteinuria (0.3 to 1 g/liter) in 39.8 and
54.5%, and "heavy" proteinuria (>1 g/liter) in 1.9 and 4.8% of
the inhabitants of two Upper Egyptian villages using a perennial
irrigation system, with a high prevalence of S. hematobium
infestation. In a control village using a continuous irrigation
system with a low prevalence of S. hematobium infestation,
only one subject had significant proteinuria. Although the renal
biopsy findings in some of these cases reported several years
later [60] were compatible with the diagnosis of schistosomal
glomerulopathy, lower UT pathology and its upper UT conse-
quences were not excluded as a potential source of proteinuria.
Concomitant S. mansoni infestation was ruled out only on
epidemiological basis, although many patients did have clini-
cally detectable hepatosplenic involvement, which was presum-
ably attributed to S. hematobium [61]. In a subsequent post-
mortem study of 268 subjects from the same country [62], there
was no correlation between glomerular abnormalities and the
presence or intensity of S. hematobium infestation. However,
in another study on 16 asymptomatic S. hematobium-infested
subjects, attending a University outpatient clinic, Soliman et a!
[63] found glomerular changes by light microscopy in 18.6% of
the renal biopsies. IgG deposits were detected in 68.8%, 1gM in
50% and schistosomal antigens in 25% of the cases. It was
concluded that S. hematobium glomerulopathy may be re-
garded as a pathological finding without corresponding clinical
disease.
Even more negative conclusions were made regarding S.
japonicum. In a recent study on 244 outpatients infested with
this species, Watt et al [64] found no association between
schistosomiasis and renal disease. Out of 100 hospitalized
patients reported by the same authors, three had significant
nephropathy, but this prevalence was not different from that in
a similar number of matching, non-infested controls. Schisto-
somal antigen could not be detected in the only biopsy obtained
from the schistosomal group.
The incidence of occult glomerular pathology among patients
with S. mansoni hepatosplenic disease was variably reported
from 12 to 40%. In a post-mortem study Andrade, Andrade and
Sadigursky [42] found a wide range of glomerular changes in
12% of subjects with hepatosplenic schistosomiasis who died of
different causes. In a subsequent prospective study, Rocha et a!
[44] found glomerular changes in six out of 15 renal biopsies
obtained during surgical splenectomy from a group of patients
who had no clinical evidence of renal disease. In a prospective
study of 69 patients with liver biopsy-confirmed hepatosplenic
schistosomiasis, Barsoum et al [65] found microalbuminuria in
15 asymptomatic patients (21.7%), of whom three had distinct
glomerular changes in renal biopsy.
The incidence of overt glomerular disease in schistosomiasis
is also difficult to estimate because of four main reasons: (1) the
general unawareness of the identity of schistosomal nephropa-
thy as a clinical syndrome; (2) the lack of adequate diagnostic
tools in the vast majority of areas where infestation is endemic;
(3) in the absence of pathognomonic diagnostic criteria (vide
infra), the question of coincidence is often raised; and (4) in S.
hematobium infestation, the clinical, laboratory and even some
histopathological features of glomerular disease can mimic
those associated with obstructive and/or reflux nephropathy
[66]. Accordingly, most of the reported series do not address
the all important issue of epidemiology. It appears, though, that
there is a remarkable difference in the clinical expression of
schistosomal glomerulopathy in different geographical areas.
Several studies have specifically denied, on statistical grounds,
the importance of schistosomal infestation in altering the prev-
alence or patterns of glomerular disease. These come from
countries like Zimbabwe [67], The Sudan [68, 69] and The
Phillipines [64]. Others, on the other hand, have incriminated S.
hematobium in the pathogenesis of the nephrotic syndrome in
up to 42.5% of patients in an endemic area [47]. In their
prospective study in Brazil, Rocha et al [44] found positive
evidence of overt renal disease in 15% of patients with S.
mansoni hepatosplenic disease. This matches with an Egyptian
series that reported an incidence of 15.9% [65].
Several questions remain open in quite a few developing
countries, where schistosomiasis is highly endemic. Has this
Fig. 1. Principal histopathological patterns in schistosomal glomerulopathy. A. Class I. Axial mesangioproliferative glomerulonephritis in a
patient with hepatosplenic schistosomiasis and microalbuminuria. (Hematoxylin and Eosin stain). B. Class II. Exudative glomerulonephritis in a
patient with hepatosplenic schistosomiasis and chronic salmonellosis. (Hematoxylin and Eosin stain). C. Class Ill-A. Early mesangiocapillary
(membranoproliferative) glomerulonephritis in a nephrotic patient with hepatosplenic schistosomiasis. (Hematoxylin and Eosin stain). D. Class
Ill-B. Type III mesangiocapillary glomerulonephritis in a nephrotic patient with mixed hepatosplenic schistosomiasis and virus B chronic active
hepatitis (Hematoxylin and Eosin stain). E. Class Ill-A. Mesangial IgA deposits, displayed by immunofluorescence, in a renal biopsy showing
advanced MCGN from a patient with hepatosplenic schistosomiasis, nephrotic syndrome, moderate hypertension and impaired renal function. F.
Class 111-B. Epi-membranous IgG deposits in the same biopsy shown in Fig. id. G. Class IV. Segmental glomeruloscierosis in a nephrotic,
hypertensive patient with hepatosplenic schistosomiasis. (Masson trichrome stain). H. Class V. Early amyloid deposits amid mesangial cell
proliferation in a nephrotic patient with mixed S. mansoni and S. hematobium infestation. (Congo red stain and polarized light examination).
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Table 1. Principal clinicopathological features of schistosomal glomerulopathy
Class
Histopathological
pattern
Glomerular deposits
detected by
immunofluorescence
Commonly
associated
infections
Hepatic
fibrosis
Features of rena1 involvement
Asymp-
tomatic
proteinuria
Nephrotic
syndrome
Hyper-
tension
Progression
to ESRD
Response
to
treatment
I
II
111
IV
V
Mesangioproliferative
a) "Minimal lesion"
b) Focal
c) Diffuse
Exudative
A. Mesangiocapillary
(type I)
B. Mesangiocapillary
(type III)
Focal & segmental
glomerulosclerosis
Amyloidosis
Mesangial: 1gM, C3,
Schistosomal gut
antigens
Endocapillary: C3,
Salmonella antigens
Mesangial: IgG, C3,
Schistosomal gut
antigens (early), IgA
(late)
Mesangial &
subepithelial: LgG, C3,
Schistosomal gut
antigens (early), IgA
(late)
Mesangial: IgG, 1gM,
IgA
Mesangial: IgG
—
Salmonellosis
—
Hepatitis B
—
?Salmonellosis
?E.coli UTI
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infestation anything to do with the very high prevalence of
glomerulonephntis? Does it modify the supervening patterns of
glomerulonephritis accordingly? Is it partly responsible for the
steroid resistance of "minimal change" nephrotic syndrome in
children, as has been reported in Africa [67, 70—73]?
Histopathological classification
Several patterns of glomerular pathology have been de-
scribed with schistosomiasis, namely mesangioproliferative,
exudative, mesangiocapillary (membranoproliferative), scleros-
ing and amyloid (Fig. 1). Transformation in between these types
has been reported in several studies, though controlled confir-
matory and quantitative longitudinal studies are not available.
There is good reason to believe that these patterns may
reflect certain geographical factors and, indeed, some pathoge-
netic differences. They certainly modify the clinical presenta-
tion and course of the disease, and may also determine the
response to treatment (Table 1). This is the rationale for the
current histopathological classification of schistosomal glomer-
ulopathies [74].
Class I: Mesangioprolferative schistosomal glomerulopathies
Simple mesangial proliferation (Fig. la) is, by far, the most
common pattern of glomerular lesions ascribed to schistosomi-
asis. Together with 1gM and C3, schistosomal worm antigen
mesangial deposits are most often encountered in this Class.
Class I lesions are the most common and earliest of schisto-
soma-associated lesions in experimental animals [34, 39]. They
have been described in 26.7 to 60% of asymptomatic patients
[44, 59, 65] and in 10 to 41,2% of those with established renal
disease [44, 48, 50, 75]. They have also been reported as the
principal lesions in grafts where schistosomal glomerulopathy
recurred shortly after transplantation [76]. There is no agent
species predilection to this Class, being reported with S.
hematobium [60], S. japonicum [56], as well as S. mansoni [77]
infestations. Its proportional contribution among other schisto-
soma-associated lesions in experimental animals does not seem
to be influenced by host species, nor are there prominent
geographical differences in its incidence among patients with
schistosomal glomerulopathy.
According to the severity and extent of mesangial prolifera-
tion, Class I lesions may be subclassified into: (a) "minimal
change" glomerulopathy, which differs from classical minimal
change disease by the presence of mesangial deposits and
variability in steroid responsiveness; (b) focal proliferative
glomerulopathy; and (c) diffuse mesangioproliferative glomeru-
lopathy. There is good reason to suggest that the differences
between these lesions are only quantitative.
As mentioned earlier, the majority of patients with features of
Class I schistosomal glomerulopathy are asymptomatic [44, 59],
or have occult urinary abnormalities [65]. Overt proteinuria
develops in an as yet undefined proportion of those patients. In
different series of patients, about one-third diagnosed with
mesangioproliferative lesions also have overt proteinuria, oc-
casionally amounting to the nephrotic syndrome [44, 65]. Hy-
pertension is unusual and renal function is seldom impaired.
Response to therapy is difficult to assess, since most series
addressing this issue do not break down the cases according to
histopathological classes. In our own experience (unpublished
data), a combination of antiparasitic chemotherapy, steroids
and azathioprine was effective in about two out of three of cases
strictly categorized within Class I boundaries.
Class II: Exudative glomerulonephritis
This type has been described mainly in patients with he-
patosplenic schistosomiasis complicated by Salmonella infec-
tion [78—80]. As the name implies, the basic glomerular pathol-
ogy is acute inflammatory, with many neutrophils, monocytes,
blood platelets and a lot of fibrin amidst the proliferating
endocapillary cells (Fig. ib) [781.
The interaction between schistosomes and different salmo-
nella strains had been described in vitro [8lJ, as well as in
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experimental animals [82], since the early seventies. Attention
to their clinical association was initially drawn in patients with
urinary schistosomiasis who used to develop recurrent episodes
of acute cystitis, and often pyelonephritis, attributed to con-
comitant Salmonella infection [83]. Although the acute symp-
toms were readily controlled by appropriate antibiotic therapy,
bacteriological cure was very difficult to achieve in the majority
of those patients, who remained as "typhoid urinary carriers"
[83] constituting an important public health problem in endemic
areas [84].
Later reports highlighted the same phenomenon in patients
with hepatointestinal schistosomiasis, who often develop Sal-
monella-associated episodes of prolonged intermittent pyrexia,
abdominal pains frequently associated with bloody diarrhea,
tender splenomegaly, vasculitic skin eruption, hair changes and
rapidly progressive secondary anemia [78, 79, 85].
It is mostly in these patients with hepatointestinal schistoso-
miasis [78, 80, 86], and occasionally in those with urinary
schistosomiasis [87] that concomitant salmonellosis was re-
ported to induce glomerular injury. The latter ushers in by a
rapidly developing nephrotic syndrome, usually without hyper-
tension or significant hyperlipidemia [78]. There is a remarkable
hyperglobulinemia [48] which is attributed to the combined
effects of polyclonal immunoglobulin response to double
chronic infections, inflammatory tissue damage, and hypoalbu-
minemia. Serum C3 has been consistently reduced in all re-
ported cases. Serum C4, on the other hand, is usually normal or
even elevated in conjunction with other acute phase reactants
[78, 86]. False positive serology for rheumatoid, syphilis and
lupus has been described in a variable proportion of cases,
which is attributed to the polyclonal B-cell stimulation.
The causative organisms can be isolated from the blood or
urine in some 80% of cases. For a conclusive bacteriological
confirmation, however, a bone marrow culture is occasionally
needed. Serological diagnosis by the well-acknowledged Widal
test is unreliable, owing to its low sensitivity and specificity in
chronic Salmonella infections [48].
The Salmonella strains involved differ according to geograph-
ical location. While S. paratyphi A [86, 78] and S. typhi [79] are
the most common in African reports, S. typhimurium [88] and
several other strains are incriminated in Brazil [89].
Several mechanisms have been suggested to explain the
interaction between schistosomiasis and salmonellosis. In the
first place, it is noteworthy that environmental and socio-
cultural factors play important roles in exposing the same
individual to both infections. The chronic immunosuppressive
status supervening in patients with chronic schistosomiasis
[90], particularly those with hepatic fibrosis [91], may interfere,
nonspecifically, with the host's defense against bacterial infec-
tion. Whether there is an added specific defect that selects an
anti-Salmonella B-cell clone is unknown.
Perhaps the most impressive mechanism is the presence of
Salmonella receptors in the tissues of adult schistosomes [92].
Once attached, the bacteria seem to share the parasite's immu-
nological advantage, thereby escaping recognition by the host's
antigen-presenting cells. This is achieved by hiding under a
cover of the host's MHC antigens and H blood group sub-
stance, which impregnate the parasite's tegument [93, 94].
Salmonella endotoxin is one of the classical inducers of
innate complement activation via the alternative pathway. The
consistent lowering of the serum level of C3, associated with
normal C4 suggests that this process indeed takes place in vivo.
The confluent C3 glomerular deposits supervening in this class
of schistosomal glomerulopathy further supports this concept,
and provides a convincing pathogenetic explanation for the
exudative nature of the glomerular pathology. That Salmonella
endotoxins are actually involved in this process has been
confirmed by immunofluorescence [80] among the plethora of
glomerular deposits characteristic of this syndrome.
Prognosis with adequate treatment is usually good, without
any appreciable loss of renal function. Although the constitu-
tional manifestations of salmonellosis as well as the acute
glomerular injury can be reversed by antibiotic therapy [79], the
disease tends to recur so long as the schistosomes remain alive
[95]. It is therefore recommended to aim at a radical cure by
combining anti-schistosomal treatment with ampicillin or amox-
acillin and cotrimoxazol [78].
Class III: Mesangiocapillary (membranoprolferative)
glomerulonephritis (MCGN)
The prevalence of this pattern among asymptomatic patients
with S. mansoni hepatointestinal disease is low, varying be-
tween 6.7 and 20% [44, 65], compared with up to 80% in those
with overt renal disease. MCGN was the predominant pattern
of glomerular pathology in a number of case reports from
different parts of the world [45, 53, 54, 96]. It was also reported
as one of the 'types' of glomerular disease associated with S.
hematobium glomerulopathy [60]. Its proportional contribution
in the histopathological profile of uncomplicated schistosomal
glomerulopathy seems to yield in favor of focal segmental
sclerosis and amyloidosis in certain African populations [50,
75]. This tendency conforms with the general pattern of glomer-
ular diseases in Africa [70—73].
According to light microscopic appearances, the lesions may
be subclassified into two patterns: (a) those of type I MCGN
(Fig. lc), characterized by mesangial cell proliferation, matrix
expansion (often described as fibrillar [77]), and interposition,
reported in 5 to 75% of clinically overt cases; and (b) those
conforming with type III MCGN (Fig ld,f), seen in less than
10% of our cases, with features of membranous nephropathy
superimposed on the conventional mesangiocapillary pattern.
The extent of mesangial cellular proliferation and matrix expan-
sion is widely variable, which is similar to experimental obser-
vations in mice (vide infra).
It is uncertain whether the "membranous nephropathy,"
which has a reported prevalence of 5 to 23.5% in different
studies, belongs to this subclass, since a detailed histological
description is seldom given. Evidence that schistosomiasis is
directly incriminated in the pathogenesis of "pure" membra-
nous nephropathy is indeed very soft, and unlike other his-
topathological patterns, still lacks convincing experimental
support.
In both subclasses of schistosoma-associated MCGN, IgG
and C3 are predominently found in the glomerular deposits.
1gM and schistosomal antigens are less often seen. IgA is
usually associated with late and/or severe lesions (Fig. le) [97].
The pattern of glomerular deposition, as seen by immunofluo-
rescence (Fig. le,f) and electron microscopy, helps to distin-
guish the two subclasses, which are essentially mesangial and
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subendothelial in subclass-A and also extramembranous in
subclass-B.
The usual clinical presentation is the nephrotic syndrome,
more gross in subclass-B. Hypertension is encountered in 40 to
50% of all cases [44, 48], but is more frequently found in
subclass-A. Clinical and/or ultrasonographic evidence of he-
patosplenic schistosomiasis was reported in almost all cases
with this pattern of schistosomal glomerulopathy. This obser-
vation has been so constant that most students in the area
regard hepatic fibrosis as an essential prerequisite for the
development of overt schistosomal glomerulopathy.
The relation of subclass-B to the hepatitis B virus is intngu-
ing. On one hand, there are those well-defined membranous
lesions often associated with mesangial proliferation and im-
mune complex deposition described with virus B infection in
Eastern Europe [98], Japan [99] and Southern Africa [100]. On
the other hand, there is also a strong association between the
hepatitus virus B infection and hepatosplenic schistosomiasis
[101, 102], in many patients leading to chronic active hepatitis
[103], mainly attributed to increased host exposure and dimin-
ished resistance [91]. It is in those patients that class Ill-B
lesions are usually encountered (unpublished data), which
suggests that viral hepatitis may "compound" the mesangial
lesions of schistosomiasis by adding the membranous element.
However, the available data are, as yet, too limited to confirm
this speculation.
The clinical course of Class III schistosomal glomerulopathy
is often progressive to global sclerosis [49, 104] without ade-
quate response to treatment, particularly in late cases [105—
109].
Class IV: Focal and segmental sclerosis (FSGS)
The prevalence of FSGS as the initial renal lesion among
patients with schistosomal glomerulopathy varies in different
series from 11.2 to 38% [43, 51, 75].
Its identity as one of the patterns of schistosomal glomeru-
lopathy is supported by experimental models in hamsters [341
and baboons [110, 111].
The glomerular lesions cannot be distinguished from those
with idiopathic FSGS (Fig. lg). Focal mesangial cell prolifera-
tion is fairly common, and schistosomal antigens have been
occasionally detected by immunofluorescence. There is a fairly
high prevalence of IgA deposits in schistosomal cases [97], an
observation that conforms with experimental findings [112].
Although these deposits may be innocent bystanders related to
the associated hepatic fibrosis [113, 114], their pathogenetic
potential [115] should not be overlooked (vide infra).
There are no specific clinical features that distinguish this
class of schistosomal glomerulopathy from others apart from
the worse prognosis. This may be partly attributed to the higher
incidence of hypertension and more profound proteinuria (un-
published data).
Class V: Amyloidosis
The prevalence of amyloidosis (Fig. lh) among other glomer-
ular lesions varies from 16.7 to 39% in different series [50, 51,
116] with an apparently higher frequency in African patients. Its
relationship with schistosomiasis is confirmed by several exper-
imental models including mice [117] and Syrian hamsters in-
Table 2. Principal pathogenetic factors in schistosomal
glomerulopathy
1. Schistosomal antigens
2. Autoimmunity
3. The "liver effect"
Porto-caval shunts
Impaired macrophage function
IgA deposition
4. Host susceptibility
fected with S. hematobium [36], or S. mansoni [35] and S.
japonicum-infected rabbits [118].
Schistosoma-associated amyloidosis is not species-depen-
dent. It has been noticed with almost equal frequency among
patients with S. mansoni and S. hematobium infestations.
Hepatic fibrosis does not seem to influence the development of
amyloidosis. In our own series, 20% of patients had evidence of
recurrent salmonellosis and 30% had persistent E. coli urinary
tract infection. The significance of these infections in the
pathogenesis of amyloidosis is uncertain (vide infra).
Patients with schistosoma-associated amyloidosis can not be
clinically distinguished from those with other forms of schisto-
somal glomerulopathy. Nephrotic syndrome is the usual pre-
sentation. Neither hypertension nor hypotension have been
observed with any higher frequency. Extra-renal amyloid de-
posits in the liver and spleen have also been occasionally
described. Whenever reported, the principal fibrillar material
was AA protein [116].
Prognosis is poor. Earlier impressions of favorable response
to anti-schistosomal treatment [119] could not be confirmed by
repeat biopsy in longitudinal studies [116].
Pathogenesis
There is convincing evidence that the initial glomerular injury
in schistosomal glomerulopathy is mediated by specific para-
sitic antigens (Table 2). Although soluble egg [38] and tegument
[120] antigens have been detected in certain studies, worm
antigens have been incriminated in the vast majority. These
have been detected as circulating antigens in infested patients
[121—124] as well as in experimentally infected animals [125—
127]. Specific antibodies of all major immunoglobulin classes
have also been detected in the sera of infested patients [128].
Although schistosomal worm antigens have occasionally
been detected before any immunoglobulins in the glomeruli of
experimental animals, they are usually found amid several other
glomerular deposits, comprising all the major immunoglobulin
classes and several complement components. These observa-
tions were made by in situ immunofluorescence [53, 75, 129—
131], as well as by indirect immunofluorescence and counter-
current electrophoresis of kidney eluates obtained from autopsy
and renal biopsy material from patients with schistosomal
glomerulopathy [60, 120].
Antigenic differences between different schistosomal species
may play a role in defining their eventual glomerular affinity.
This is particularly prominent in experimental animals, where
glomerulonephritis can be readily induced by S. mansoni and S.
japonicum, but not by S. hematobium [132], amyloidosis being
an exception [36]. In this context, it is noteworthy that despite
an almost equal prevalence of S. hematobium and S. mansoni in
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Fig. 2. The "liver effect" in the pathogenesis
of schistosomal glomerulopathy. Soluble egg
antigens (SEA), specific IgA of colonic origin
and circulating worm antigens (CWA) are
carried along the portal vein (solid lines) to
the liver, where they are cleared or
modulated. In the presence of porto-systemic
shunts [I] or impaired hepatic macrophage
functions [2], schistosomal antigens as well as
mucosal IgA may find their way to the
systemic circulatioii [dashed lines], provoke
an 1gM and/or IgG response, leading to
glomerular immune deposits.
Africa, it is the latter that has been mostly associated with
glomerulopathy, with only a few exceptions [47, 54, 133] which
have been subsequently challenged [62, 66].
Even within the same species differences in strains [134] may
also reflect on glomerular pathogenicity. In addition to its
epidemiological importance [135], this issue may be of immu-
nological interest if antigenic differences in between those
strains are identified.
Out of over a hundred schistosomal antigens isolated in vitro,
only a few have been also identified as circulating antigens in
vivo [121, 122, 136, 137]. These mostly originate from the gut of
adult worms, as the latter regurgitate their digestive juices into
the host's blood stream. Relatively more recent studies have
shown that it is those gut antigens that are mostly detected in
the glomerular deposits [75, 129, 130, 138].
Mesangial localization of immune complexes containing gut
antigens is the rule. Yet the extramembranous IgG deposits
encountered in some experimental models [139] and cases [60]
of schistosomal glomerulopathy suggest that in situ immune
complex formation may take place as well. Relevant to this
suggestion is the demonstration of glomerular deposits of
"free" schistosomal antigens in experimental animals [38] and
of the closely associated anti-HBV antibodies in humans [140].
The chances of detecting schistosomal antigens are reduced
with progression of the lesions. Although some studies have
found a positive correlation between the development of gb-
merulopathy and the infecting cercarial load in animals [35, 36,
141] or the intensity of infestation in patients [30], the severity
of the lesions does not seem to depend on such parameters [35,
142]. These data may suggest that despite the importance of
schistosomal antigens in the initiation of glomerular pathology,
other factors may have something to do with the further
evolution of the lesions.
Autoimmunity is one eligible mechanism of progression.
Reference has been made earlier to the polyclonal B-cell
response in schistosomiasis [143], particularly when associated
with hepatic fibrosis [144, 145]. The remarkable hyperglobulin-
emia described in most clinical reports includes elevation of the
major three immunoglobulin classes [48, 128, 146] and may
explain the "false positive" serology for rheumatoid factor,
ANF, VDRL and others. Anti-nuclear antibodies have been
found in the sera and glomerular deposits in experimental
animals [147] as well as in humans [148] with schistosoma-
induced glomerulopathy. The public anti-DNA idiotype 16/6 ID
and anticardiolipin antibodies have been recently found in the
sera of patients with chronic S. mansoni infestation; the pattern
of their serum levels was distinctive in those with glomerular
involvement [149]. Antiglomerular basement membrane anti-
bodies have been described in almost one-third of the patients
in a recently reported series [150].
Although these observations suggest a potential role of auto-
immunity in the progression of schistosomal glomerulopathy, as
yet there is no direct evidence that they perpetuate or enhance
glomerular pathology.
Another factor commonly associated with evolution of the
glomerular lesions is hepatic fibrosis. This is probably one
reason why S. mansoni has been most frequently associated
with glomerulopathy. In most animal models, liver fibrosis
usually precedes [33, 151] and often correlates [41, 110] with the
glomerular lesions. As mentioned earlier, conforming clinical
and post-mortem observations have been made in humans.
Even with S. hematobium-associated glomerulopathy, hepatic
fibrosis has been reported as a prerequisite for the development
of glomerular lesions in mice [152] and is described in a large
proportion of reported clinical material [60].
The "liver effect" is not attributed to hepatocellular injury
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Fig. 3. Suggested three phase evolution (from
left to right) of schistosomal glomerulopathy.
[153], nor to disorders of lymphocyte subpopulations [144, 145,
154], or serum immunoglobulin or complement profiles [153].
Margination of the liver, as in the experiments where the portal
vein is ligated in mice [151] or in those where a portocaval shunt
was created in chimpanzees [155], seems to be the crucial
factor. It appears that deprivation of the immune-modulating
functions of the liver [156] permits circulating schistosomal
antigens to build up to the critical levels needed for glomerular
deposition.
It is generally accepted that shunting of portal blood, carrying
the primary load of worm antigens, into the systemic circulation
is the main mechanism by which the liver is "marginated" in
patients with schistosomal glomerulopathy. Yet, in a recent
study using technitium-labeled sulphur colloid clearance curves
[157], it was shown that the severity of glomerular lesions, as
well as proteinuria, correlated with impairment of hepatic
macrophage function [97]. These data suggest that hepatic
bypass may also be a functional consequence of hepatic fibro-
sis, in addition to the physical shunting of portal blood.
In the same study [97], it was shown that impairment of
hepatic macrophage function also correlated with glomerular
IgA deposits which, like in a mouse model [112], were mainly
seen in advanced lesions. This suggests that the spectrum of
"hepatic Inargination" in schistosomal glomerulopathy in-
cludes impaired clearance of IgA [158, 159], which may add to
the glomerular injury by its own right [114, 115] (Fig. 2).
Racial and genetic factors may be involved in defining the
development and severity of schistosomal glomerulopathy. In
the first place, it is known that racial factors are important in the
susceptibility to infestation [160, 161], and its acute [162] and
chronic complications [28]. Genetic factors modify the immune
response to schitosomal antigens [163]. They are also involved
in defining the susceptibility to certain complications. This is
suggested by the association between HLA-B5 and S. mansoni
intestinal polyposis [164], Al, B5 with hepatic fibrosis [165],
and A28 with glomerular disease [166].
Schistosoma-associated amyloidosis may be a variant of the
host's immune response to persistent antigenic stimulation
[167]. Despite contradictory data in hamsters [35, 361, no
clinical correlation has been reported between the development
of amyloidosis and the duration and intensity of infestation. In
most studies, the mean age of patients with this class of
schistosomal glomerulopathy was even younger than that for
other classes. It was mostly sex-linked, males being more
commonly affected. Together with the distinct geographical
variation in the prevalence of this class [30, 116], these data
suggest the involvement of genetic influence in its pathogenesis.
Such factors may influence the kinetics of the host's immune
response, thereby generating the right immune complexes
[168], or the macrophage/monocyte/mesangial response,
thereby favoring amyloidogenesis. Studies in this particular
aspect of the pathogenesis of schistosomal glomerulopathy are
under way.
In summary, the available data on the pathogenesis of schis-
tosomal glomerulopathy suggest that the disease may be tripha-
sic (Fig, 3). Mesangial deposition of circulating gut, and possi-
bly soluble egg antigens of different schistosomal species almost
certainly induces the initial glomerular injury which usually
manifests by mesangial hypercellularity (Class I lesions) with
only a few clinical sequelae. Further progression into the
second phase of overt renal disease seems to be more complex,
involving a multiplicity of agent and host factors that ultimately
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determine the predominent line of pathological evolution into
one or another of the four classes characterized respectively by
exudative, mesangiocapillary (membranoproliferative), focal
and segmental sclerosing or amyloid glomerulopathies. The
final progression into end-stage renal disease may be even less
specific, obeying the general rules of late glomerular pathology
that supervene in other diseases regardless of etiology.
RASHAD S. BARSOUM
Cairo, Egypt
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